Latest News

  • Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020 Read More
  • Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results Read More
  • Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

Working at Alkermes

career opportunities at Alkermes
Working at Alkermes Join Our Team